Difference between revisions of "MEDICATION-LIGNOCAINE"
From NeuroRehab.wiki
(Imported from text file) |
(Imported from text file) |
||
| Line 1: | Line 1: | ||
[[ | [[Summary Article|<h5>'''SUMMARY ARTICLE'''</h5>]] | ||
<br/> | <br/> | ||
<div>1. Acts as a membrane stabilising agent, used for its anti-arrhythmic effects.<div>2. Indications: VF/pulseless or VT refractory to defibrillation.</div><div><br></div><div>SE</div><div>3. Nausea & vomiting.</div><div>4. CNS: slurred speech, drowsiness, seizures.</div><div>5. CVS: bradycardia, heart block, asystole. </div><div><br></div><div>DOSAGE</div><div>6. Initially 1 mg/kg bolus after the third DC shock, additional bolus of 0.5 mg/kg (up to 200 mg) may be considered. </div> | <div>1. Acts as a membrane stabilising agent, used for its anti-arrhythmic effects.<div>2. Indications: VF/pulseless or VT refractory to defibrillation.</div><div><br></div><div>SE</div><div>3. Nausea & vomiting.</div><div>4. CNS: slurred speech, drowsiness, seizures.</div><div>5. CVS: bradycardia, heart block, asystole. </div><div><br></div><div>DOSAGE</div><div>6. Initially 1 mg/kg bolus after the third DC shock, additional bolus of 0.5 mg/kg (up to 200 mg) may be considered. </div> | ||
Revision as of 11:26, 19 December 2022
SUMMARY ARTICLE
1. Acts as a membrane stabilising agent, used for its anti-arrhythmic effects.
2. Indications: VF/pulseless or VT refractory to defibrillation.
SE
3. Nausea & vomiting.
4. CNS: slurred speech, drowsiness, seizures.
5. CVS: bradycardia, heart block, asystole.
DOSAGE
6. Initially 1 mg/kg bolus after the third DC shock, additional bolus of 0.5 mg/kg (up to 200 mg) may be considered.
Reference(s)
Gale, M., Grantham, H., Morley, P. and Parr, M. (2016). Advanced Life Support Level 1: 3rd Australian Edition. Australian Resuscitation Council.
American College Of Surgeons. Committee On Trauma (2012). ATLS : student course manual. Chicago, Ill.: American College Of Surgeons.
